On Monday, Shares of Amazon.com, Inc. (NASDAQ:AMZN), gained 0.06% to $664.51.
Amazon declared that Amazon Original Series The Man in the High Castle, recently renewed for a second season, is the most-streamed original show ever by Prime members globally. The show broke a previous record set by Amazon Original Series Bosch—which is launching its second season next year. Based on the award-winning book by Philip K. Dick, developed by Frank Spotnitz and Executive Produced by Scott Free Productions’ Ridley Scott and David Zucker, together with Isa Dick Hackett, the show is available exclusively on Amazon Prime.
Amazon.com, Inc. operates as an online retailer in North America and internationally. It operates through the North America, International, and Amazon Web Services (AWS) segments. The company serves consumers through retail websites, such as amazon.com, amazon.ca, and amazon.com.mx, which primarily comprise merchandise and content purchased for resale from vendors and those offered by third-party sellers.
Shares of Actinium Pharmaceuticals Inc (NYSEMKT:ATNM), inclined 14.54% to $2.60, during its last trading session.
Actinium Pharmaceuticals, is a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers. The Company declared recently that the FDA has cleared the Company’s IND filing for Iomab-B, and that it will proceed with the pivotal, Phase 3 clinical trial. Actinium anticipates the Phase 3, controlled, randomized, pivotal trial to start enrolling in the first half of 2016 and assuming that the trial meets its end points, it will form the basis for a Biologics Licensing Application (BLA). Actinium also indicated that it will update investors with further details on the company’s pipeline counting new programs and product candidates from its APIT (alpha particle immunotherapy) platform at its R&D Day in Q1:2016.
“After a challenging twelve month period, we are happy to have the Iomab-B IND cleared and to be in a position to proceed with the pivotal, Phase 3 trial. In anticipation of this much awaited milestone, we have plannedally expanded our core team in recent months and strengthened the balance sheet to prepare for not only the forthcoming Phase 3 trial for Iomab-B but also the predictable Phase 2 trial for Actimab-A, our novel CD33 targeting construct. The IND clearance represents the elimination of a major risk factor that had been hampering Actinium’s progress and our entire team is energized by the achievement of this milestone. This event is a major catalyst that signals Actinium’s transformation in 2016 from an early clinical stage company to a later stage company with two product candidates that have the potential to be major medical advances. We look forward to updating investors and potential partners about all of our programs at our R&D Day in Q1:2016,” said Sandesh Seth, M.S., MBA, Executive Chairman of Actinium Pharmaceuticals, Inc.
“The clearance of the IND for Iomab-B is a major milestone for Actinium Pharmaceuticals,” said Kaushik Dave, Ph.D., MBA, Chief Executive Officer of Actinium Pharmaceuticals, Inc. “Our team has worked extremely hard this year to prepare our IND filing with noteworthyfocus being placed on our Chemistry, Manufacturing and Controls efforts. With the IND now cleared, we are eager to ramp up our clinical development activities related to the pivotal, Phase 3 Iomab-B trial.”
Actinium Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs for the treatment of cancer. The company develops therapies for life threatening diseases using its alpha particle immunotherapy platform and other related and similar technologies.
Finally, Biodel Inc (NASDAQ:BIOD), ended its last trade with -11.86% loss, and closed at $0.271.
Biodel Inc., stated financial results for the fourth fiscal quarter and year-ended September 30, 2015. Additionally, the Company declared that its Board of Directors has approved a plan to explore planned alternatives to further realize value from its pipeline assets and to preserve the Company’s noteworthy cash balance. As part of this plan, enrollment in BIOD-531 Study 3-157 is being suspended and the Company will retain an advisor to assist in this process of evaluating its planned alternatives.
Dr. Errol De Souza, president and chief executive officer of Biodel, stated: “The impact of the delay of the timelines for filing the NDA for the Glucagon Emergency Administration product candidate on our stock price has necessitated us to commence a review our planned alternatives while at the same time extending our cash runway. While this is a difficult decision, we believe it offers the best opportunity to maximize shareholder value from our clinical assets and cash resources. I look forward to being able to update our investors on the process in the coming months.”
Fourth Quarter Financial Results
Biodel stated a net loss of $3.2 million and $18.7 million, or $0.05 and $0.46 per share for the quarter and twelve month period ended September 30, 2015, respectively. These results compare to a net loss of $2.3 million and $14.1 million, or $0.10 and $0.66 per share for the quarter and twelve month period ended September 30, 2015, respectively.
Biodel did not recognize any revenue during the quarter and twelve month period ended September 30, 2015 or 2014.
At September 30, 2015, Biodel had cash and cash equivalents of $40.8 million and 62.2 million shares of common stock outstanding.
Biodel Inc., a specialty biopharmaceutical company, focuses on the development and commercialization of treatments for diabetes in the United States. Its lead product candidate is a glucagon emergency administration (GEM) device that is intended to treat diabetes patients experiencing severe hypoglycemia, or very low concentrations of blood glucose.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.